← All trials
NCT07022223
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 11, 2025
- Primary completion
- Sep 11, 2027
- Completion date
- Sep 11, 2029
- First posted
- Jun 15, 2025
- Last posted
- Jun 15, 2025
- Enrollment
- 51
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang UniversityLead sponsor
- Dongyang People's HospitalCollaborator
- Nanchang UniversityCollaborator
- Huzhou UniversityCollaborator
- Shaoxing People's HospitalCollaborator
- Nanchang UniversityCollaborator
- Zhejiang UniversityCollaborator
- Yuyao People's Hospital of Zhejiang ProvinceCollaborator
- Wenzhou Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Ningbo No. 5 HospitalCollaborator
- The Central Hospital of Lishui CityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Zhuji People's hospitalCollaborator
- Shaoxing Central HospitalCollaborator
- People's Hospital of QuzhouCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.